Peer-reviewed veterinary case report
Stem cell and antibody treatment for feline panleukopenia
By Wang, Yi et al.·Published in Stem cell research & therapy·2026·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Investigation of the clinical efficacy of mesenchymal stem cells in combination with monoclonal antibody therapy against feline panleukopenia.
- Species:
- cat
Plain-English summary
A group of 15 kittens aged 2 to 4 months with feline panleukopenia (a serious viral infection) were treated to see if mesenchymal stem cells (MSCs) could help improve their condition. While the control group and those receiving standard treatment saw their white blood cell counts drop dangerously low, the kittens receiving MSCs showed an increase in their white blood cell counts after treatment, which is a positive sign for recovery. Unfortunately, one kitten did not respond well and passed away, but overall, the MSC treatment showed promise in improving survival rates and clinical symptoms in affected kittens.
People also search for: kitten panleukopenia treatment · feline panleukopenia symptoms · mesenchymal stem cells for cats · how to help sick kittens · kitten white blood cell count low
Abstract
BACKGROUND: Feline panleukopenia is an acute and highly contagious disease caused by feline panleukopenia virus (FPV). Conventional therapeutic approaches often yield suboptimal outcomes in managing leukopenia, which consequently contributes to its high mortality rate. Mesenchymal stem cells (MSCs) are a type of multipotent stem cell characterized by their multidirectional differentiation potential and immunomodulatory capabilities. Studies have shown that MSCs possess the potential to treat inflammatory and immune-mediated diseases, support and promote hematopoiesis, and facilitate tissue repair. Therefore, this study was to investigate the clinical efficacy of combining MSCs with feline panleukopenia monoclonal antibody to propose a potential treatment for FPV. METHOD: MSCs were extracted from a newborn kitten's umbilical cord tissue. Fifteen healthy unimmunized kittens aged 2 to 4 months were divided evenly into three groups: control group, conventional treatment group, and MSCs group (conventional treatment combined with MSCs therapy, involving daily intravenous administration of 1 × 10MSCs for 3 consecutive days). Treatments were commenced once evident clinical symptoms manifested and white blood cell counts declined below the normal range. The subject cats were assessed for clinical signs, complete blood count (CBC), blood biochemistry, serum amyloid A (SAA), pathology and viral load in major organs. RESULT: The results revealed that in the control group and conventional treatment group, cats exhibited a rapid decline in white blood cell count following disease onset, ultimately resulting in mortality. Conversely, in the MSCs group, four cats demonstrated an increase in white blood cell count post-treatment, subsequently returning to normal levels. However, one cat did not exhibit a significant increase and died on the third day of treatment. CONCLUSION: These findings highlight the therapeutic potential of MSCs in elevating leukocyte counts, improving clinical symptoms, and ultimately leading to a significant enhancement of survival rates among FPV-affected cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/42026664/